VETERINARY PAIN MANAGEMENT MARKET ANALYSIS

Veterinary pain management is a crucial part of veterinary therapeutics. Pain in animals leads to delayed healing and exaggerated stress in already sick animals. Pain in animals could be due to cancer, arthritis, and surgeries, and may lead to reduced activity and aggression. The most important aim is pain management while efforts are made to spot and treat underlying disease and reinforce healing and recovery. Pain management practice provides veterinary practitioners with the information needed to recognize and manage pain in a wide range of large, small, and exotic animals. Non-steroidal anti-inflammatory drugs are one of the most commonly used and most effective drug in the treatment of pain due to arthritis or after surgery.

Market Statistics:

The global veterinary pain management market was valued at US$ 1,407.8 Mn in 2021 and is forecast to reach a value of US$ 2,154.9 Mn by 2028 at a CAGR of 6.3% between 2022 and 2028.

North America held dominant position in the global veterinary pain management market in 2020, accounting for 40.5% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Veterinary Pain Management Market Share (%), by Region, 2021

To learn more about this report, request a free sample copy

Recent Developments:

In June 2020, Chanelle Pharma received the Food and Drugs Administration (FDA) approval to manufacture Spot on in the US market. Spot On is a topical treatment used to protect cats and dogs against parasites.

In September 2020, Boehringer Ingelheim International Gmbh acquired an equity stake in New Ruipeng Group (NRP Group), a Chinese company involved in veterinary care, e-commerce, and other services.

In April 2020, Ceva Sante Animale launched the cattle pain campaign to raises awareness about the importance of pain reliefs in lame cattle.

Market Drivers:

1. Growing prevalence of animal disease causing pain and inflammation is expected to augment growth of the global veterinary pain management market over the forecast period. For instance, pain is a widespread clinical symptom in companion animals with cancer, and its aggressive management should be a priority. Pain can significantly decrease the quality of life of animals with cancer. According to the National Cancer Institute, around 6 million new cancer diagnoses are made in dogs each year. Moreover, around 6 million dogs and 6 million cats are diagnosed with cancer each year, according to the Animal Cancer Foundation.
2. Growth in companion animal adoption is expected to boost growth of the global veterinary pain management market during the forecast period. The companion animal segment accounted for the largest share of the market, due to increasing awareness about animal health and rising pet healthcare expenditure. For instance, according to the American Society for the Prevention of Cruelty to Animals, more than 6 million companion animals (3 million dogs and 3 million cats) enter U.S. animal shelters nationwide every year.

Figure 2. Global Veterinary Pain Management Market Share (%), by Product, 2021

To learn more about this report, request a free sample copy

Market Restraints:

1. High cost of certain products is expected to hamper the growth of the global veterinary pain management market. For instance, in the emerging markets where there is an absence of animal insurance, the cost of certain veterinary pain management products are too high for individuals to bear. The average cost for laser therapy in chronic pain is around US$ 25 to 35 per treatment, and treatment costs are quite high as multiple laser therapy sessions are required. As a result, many people tend to shift towards off-label products.
2. Side effects associated with treatment is expected to hinder growth of the global veterinary pain management market. Non-steroidal anti-inflammatory drugs (NSAID) are one of the most commonly used and most effective drug in the treatment of pain due to arthritis or after surgery. Vomiting, decreased to no appetite, decreased activity level, and diarrhea are some of the most common side effects of NSAIDs in animals reported to the Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine.

Market Opportunities:

1. Increase in awareness about animal health and welfare is expected to offer lucrative growth opportunities for players in the global veterinary pain management market. For instance, rise in awareness about animal health and welfare has improved animal healthcare and has led to the increasing demand for pain management products. The Cattle Health and Welfare Group (CHAWG), in the United Kingdom, is playing a crucial role in addressing relevant cattle health and welfare issues. In the U.K., CHAWG acts as the first point of call for all cattle health and welfare research, along with new disease challenges.
2. Favorable initiatives by the government and other organizations is expected to offer lucrative growth opportunities for players active in the global veterinary pain management market. For instance, in October 2020, FECAVA announced the launch of the campaign, FECAVA Basic Practices in Anesthesia and Analgesia, which will include important lectures around Europe in the upcoming years and a series of six ready-to-use, printable posters or infographics regarding anesthesia and pain management in animals.

Market Trends/Key Takeaways:

1. Increase in demand for pain management is expected to drive growth of the global veterinary pain management market. For instance, in January 2022, U.S. Food and Drug Administration (FDA) approved Solensia (frunevetmab injection), the first treatment to control pain associated with osteoarthritis (OA) in cats.
2. Rising prevalence of inflammatory diseases in animals worldwide is expected to propel the growth of the global veterinary pain management market. For instance, according to an article published in June 2020 by Veterinary Practice News, the prevalence of osteoarthritis in dogs was found to be 20% worldwide, making it the most common chronic disease they face.

Competitive Landscape:

1. Assisi Animal Health
2. Boehringer Ingelheim International GmbH
3. Ceva Sante Animale
4. Chanelle Veterinary Limited
5. Dechra Pharmaceuticals PLC
6. Elanco Animal Health Incorporated
7. Norbrook
8. Vetoquinol SA
9. Zoetis Inc.